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Introduction
Myofibroblasts contribute to normal tissue repair by replacing 
and contracting the provisional ECM that fills tissue defects 
after injury (Hinz et al., 2012). When ECM remodeling activi-
ties of myofibroblasts are deregulated, repair proceeds into ad-
verse and pathological fibrosis affecting all organs, including 
skin, heart, lung, liver, and kidney (Hinz et al., 2012; Wynn 
and Ramalingam, 2012). TGF-1 is the most potent profibrotic 
cytokine known and the main growth factor inducing myofibro-
blast differentiation from a variety of different precursor cells 
(Hinz et al., 2007). Fibroblasts secrete TGF-1 noncovalently 
associated with its latency-associated propeptide (LAP). This 
small latent complex covalently binds to the LTBP-1, an inte-
gral component of the ECM that stores and presents latent 
TGF-1 for subsequent activation (Jenkins, 2008; Worthington 
et al., 2011; Zilberberg et al., 2012; Robertson and Rifkin, 
2013). Binding of LAP to the ECM through the LTBP-1 is the 
structural precondition for mechanical activation by integrins 
(Annes et al., 2004; Wipff et al., 2007; Shi et al., 2011). The 
LTBP-1 binding site of LAP is directly opposite to the RGD site 
in LAP for integrin attachment; integrin-mediated force trans-
mission induces a conformational change in LAP that liberates 
active TGF-1 (Buscemi et al., 2011; Shi et al., 2011). All v 
integrins bind to RGD in LAP (Jenkins, 2008; Wipff and Hinz, 
2008; Nishimura, 2009; Henderson and Sheppard, 2013; Hinz, 
2013). Integrins v3, v5, v6, and possibly v1 activate 
latent TGF-1 by transmitting cell contractile forces (Wipff 
et al., 2007; Giacomini et al., 2012; Henderson et al., 2013).
We have previously demonstrated that the acute contrac-
tile state, i.e., the force exerted by fibroblastic cells, determines 
the quantity of TGF-1 that is activated from the ECM (Wipff 
et al., 2007; Buscemi et al., 2011). Here, we propose that the 
changes in ECM organization produced by fibroblastic cells 
over days, weeks, and months in fibrotic lesions will augment 
the bioavailability of TGF-1. We show that myofibroblasts 
Integrin-mediated force application induces a confor-mational change in latent TGF-1 that leads to the release of the active form of the growth factor from 
the extracellular matrix (ECM). Mechanical activation 
of TGF-1 is currently understood as an acute process 
that depends on the contractile force of cells. However, 
we show that ECM remodeling, preceding the activation 
step, mechanically primes latent TGF-1 akin to load-
ing a mechanical spring. Cell-based assays and unique 
strain devices were used to produce a cell-derived ECM of 
controlled organization and prestrain. Mechanically con-
ditioned ECM served as a substrate to measure the efficacy 
of TGF-1 activation after cell contraction or direct force 
application using magnetic microbeads. The release of 
active TGF-1 was always higher from prestrained ECM 
as compared with unorganized and/or relaxed ECM. The 
finding that ECM prestrain regulates the bioavailability of 
TGF-1 is important to understand the context of diseases 
that involve excessive ECM remodeling, such as fibrosis 
or cancer.
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produced by low contractile hDfs, as quantified by LTBP-1 
density in fibrils (Fig. 1, B and D). To compare the potential of 
hDfs and hDMfs to activate TGF- from their differently orga-
nized ECM, we induced cell contraction with thrombin. Active 
TGF- was measured using directly co-cultured transformed 
mink lung epithelial cells (TMLCs) and normalized to total 
levels of TGF- measured in heat-activated cell/ECM lysates. 
TMLC reporting was abolished by adding TGF-1–blocking 
antibodies to contraction-stimulated hDMf/TMLC co-cultures 
(Fig. S1 C), identifying TGF-1 as the main isoform in hDMf 
cultures. Low concentrations of thrombin (0.5 U/ml) exerted 
no proteolytic action on either ECM or latent TGF-1 (Fig. S1, 
D and E), confirming previous controls with other fibroblast 
sources (Wipff et al., 2007; Sarrazy et al., 2014). Thrombin-
induced cell contraction and ECM deformation resulted in me-
chanical TGF-1 activation similar to inducing cell contraction 
with TRAP-6 (thrombin receptor activating peptide 6), bearing 
no catalytic activity (Fig. S1, F and G). Contraction-induced 
active TGF-1 levels were threefold higher in hDMf (36% 
of total TGF-) than in hDf (11%) cultures (Fig. 1 E). Base-
line levels of active TGF- without addition of thrombin were 
low in both cell types (≤2%; Fig. 1 F). Total levels of TGF- 
were only moderately higher in hDMf than in 6-d-old hDf 
cultures (Fig. 1 G).
Mechanical activation of TGF-1 increases 
with increasing maturation of the ECM
Next, we tested whether the higher levels of active TGF-1 
in hDMf cultures are related to ECM properties rather than to 
the TGF-1–activating fibroblast phenotype. hDfs and hDMfs 
were cultured to produce latent TGF-1–containing ECM for 
2, 3, and 6 d. LTBP-1 expression in hDMf cultures was detect-
able by 3 d and increased by 6 d; FN (total and ED-A FN) was 
detected already after 2 d and increased only moderately over 
culture time (Fig. 2 A). LTBP-1 and FN expression levels in hDf 
cultures followed the same time course but were lower than in 
hDMf cultures (not depicted and Fig. 1). The differently pro-
duced and matured ECMs were then decellularized using des-
oxycholate (DOC), and total TGF-1 levels were measured. In 
the 3-d- and 6-d-old decellularized ECM, total TGF-1 levels 
were similar and only moderately higher (1.25-fold) in hDMf 
than in hDf cultures (Fig. 2 B). However, when hDMfs were 
reseeded onto all decellularized ECMs and induced to contract, 
an approximately twofold increase in active TGF-1 (percent-
age of total) was observed on the 6-d mature versus the 3-d 
immature ECM (Fig. 2 C). Moreover, approximately twofold 
more TGF-1 was released by reseeded hDMfs from hDMf-
remodeled ECM than from hDf-remodeled ECM of the same 
“age” (Fig. 2 C). To relate TGF-1 activation with LTBP-1 
organization in the ECM, we transfected EGFP-tagged LTBP-
1 into hDMfs. LTBP-1–EGFP colocalized with endogenous 
LTBP-1 in the ECM (Fig. 2 D). In 2-d-old ECM, LTBP-1 was 
almost exclusively localized in patches at the substrate surface 
that became increasingly organized into ED-A FN-containing 
fibrils after 3- and 6-d culture (Fig. 2, E and F). These results 
indicate that the efficacy of mechanical activation of TGF-1 
mechanically prime TGF-1 for activation by actively organiz-
ing the latent complex in the ECM during and after secretion, 
analogous to the loading of a mechanical spring. High levels of 
experimentally controlled ECM organization and mechanical 
load always resulted in high levels of TGF-1 activated by 
acutely contracting myofibroblasts. Our results suggest that the 
excessive remodeling activity of fibroblastic cells in the early 
stages of tissue repair will set the stage for the development 
of fibrosis by adjusting the mechanical trigger point for latent 
TGF-1 activation.
Results
Myofibroblast differentiation leads to 
increased ECM organization  
and TGF-1 activation
To test whether de novo formation of myofibroblasts and in-
creased tissue stress in vivo are associated with higher fibril-
lar organization of ECM in general and LTBP-1 in particular, 
we used a rat model of mechanically enhanced wound healing 
(Hinz et al., 2001b). The dermis of normal rat skin exhibited 
negligible levels of the fibronectin (FN) splice variant ED-A FN, 
and LTBP-1 and no -smooth muscle actin (-SMA)–positive 
myofibroblasts (Fig. 1 A). After dermal wounding, neoexpres-
sion of ED-A FN (day 3–4) preceded the first appearance of 
LTBP-1 and myofibroblasts (day 6–7) in the granulation tissue, 
with all proteins reaching peak expression at day 9 (Fig. 1 A). 
The alignment of ECM fibrils in parallel to the skin surface 
moderately increased over time of normal healing (Fig. 1 A). 
In contrast, mechanically restraining the wound edges with 
splints accelerated ED-A FN, LTBP-1, and -SMA expression 
by 3 d and led to substantially higher fibril organization at 
any given time compared with normal wounds. Differences be-
tween normal and splinted wounds were most pronounced 9 d 
after wounding, as shown by quantifying LTBP-1 fibril density 
by image analysis (Fig. 1 A). Enhanced LTBP-1 organization 
correlated with the enhanced TGF-1 downstream signaling 
(pSmad2/3 phosphorylation) and -SMA expression reported 
in our previous studies using the same rat model (Hinz et al., 
2001b; Wipff et al., 2007).
To discriminate the role of the ECM strain in guiding fi-
brillar organization of LTBP-1 and availability of associated 
latent TGF-1, we established controlled experimental condi-
tions. High-contractile human dermal myofibroblasts (hDMfs) 
were generated by treating primary human dermal fibroblasts 
(hDfs) with active TGF-1 once for 5 d in passage 1. TGF-1 
used to differentiate hDMfs was not detectable in passage 4 
when hDMfs were assessed experimentally (Fig. S1, A and B). 
In contrast to the small population of cells (7 ± 5%) expres-
sing the myofibroblast marker -SMA in contractile stress fibers 
in standard culture conditions, the hDMf fraction represented 
40 ± 15% of the cell population, even three passages after 
TGF-1 stimulation (Fig. 1 B and Fig. S1, A and B). Higher 
protein expression levels of -SMA in hDMfs correlated with 
higher expression of LTBP-1 and ED-A FN (Fig. 1, B and C). 
Organization of LTBP-1 and colocalization with ED-A FN in 
the myofibroblast ECM was threefold higher than in the ECM 
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Figure 1. Changes in ECM composition and structure during myofibroblast differentiation. (A) Granulation tissue sections of splinted and nonsplinted 
wounds from female Wistar rats were stained for -SMA (blue), ED-A FN (red), and LTBP-1 (green). Normal rat skin is compared with 3-d-old nonsplinted 
wounds. Additionally, the arrowhead indicates the region of granulation tissue that is compared from splinted and nonsplinted wounds at day 3, 6, 
and 9. Insets show LTBP-1 only. Bars, 10 µm. (B) hDfs (control) were differentiated into hDMfs using 2 ng/ml TGF-1 for 5 d in passage 1 (+TGF-
1) and used at passage 4 after 6 d of growth. Cells were labeled for -SMA and F-actin and for LTBP-1, ED-A FN, and nuclei (blue). Bars, 50 µm. 
(C) Expression of ED-A FN, LTBP-1, vinculin, and -SMA was determined by Western blotting of cells grown without (control [con]) and with TGF-1 and 
quantified as a percentage of control normalized to vimentin as a loading control. (D) The mean density of fibril events per image field was quantified 
from 14 LTBP-1–stained images per three independent experiments. (E and F) Active TGF-1 was measured by directly co-culturing fibroblastic cells with 
TMLC reporter cells either after inducing cell contraction with thrombin (E) or without inducing cell contraction (F, baseline). (G) Levels of active TGF-1 
are presented as a percentage of total TGF-1 determined from heat-activated ECMs and cells. Graphs show mean values and SDs from at least three 
independent experiments (*, P ≤ 0.05; two-tailed paired t test). a.u., arbitrary unit.
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and hDfs were then added to process the prefabricated ECM in 
FN-depleted medium for 2 d (Videos 1 and 2 and Fig. S3 A). Dur-
ing this time, the endogenous production of LTBP-1 was negligi-
ble (Fig. 2). Organization of the supplied LTBP-1–EGFP into 
ECM fibrils was significantly higher in hDMf than in hDf cul-
tures in all three experimental models (Fig. 3).
LTBP-1 incorporation into the ECM was previously shown 
to depend on FN secretion (Taipale et al., 1996; Dallas et al., 
2000; Massam-Wu et al., 2010; Todorovic and Rifkin, 2012; 
Zilberberg et al., 2012), and binding of LTBP-1 to FN is es-
sential for integrin-mediated activation of TGF-1 (Annes et al., 
2004). To test whether fibroblastic cells organize LTBP-1 
directly or indirectly by hitchhiking on FN fibril formation, we 
knocked down FN in hDMfs using specific siRNA (Fig. S3 B). 
FN-deficient hDMfs were able to attach and spread onto LTBP-1– 
coated substrates but failed to form LTBP-1 fibrils (Fig. 4 A). 
Similar results were obtained using FN/ mouse embryonic fi-
broblasts (MEFs; Fig. 4 B), confirming that the presence of FN 
is indeed crucial for LTBP-1 fibril formation. hDMfs produced 
higher amounts of FN than hDfs during LTBP-1 fibril forma-
tion (Fig. 1 and Fig. 3). To evaluate whether higher FN quanti-
ties accounted for the higher efficiency of hDMfs to produce 
LTBP-1–containing fibrils, we restricted the culture time of hDfs 
correlates with the level of FN fibril formation and organization 
of the ECM in addition to the acute contractile state of the fi-
broblastic cells.
Myofibroblasts incorporate LTBP-1 into 
strained ECM fibrils in an integrin-mediated 
and actin–myosin-dependent process
Thus far, our results suggest that a higher degree of ECM organi-
zation contributes to the increased ability of hDMfs to generate 
active TGF-1 compared with hDfs. To determine the remodel-
ing capacities of hDMfs and hDfs independently of LTBP-1/ECM 
secretion, we preproduced LTBP-1–containing ECM in three dif-
ferent ways (Fig. 3). First, HEK293 (human embryonic kidney-
293) cells were stably transfected with LTBP-1–EGFP and used 
to generate an ECM enriched in EGFP-tagged LTPB-1. The 
HEK293 cells were not able to organize FN or the secreted 
LTBP-1–EGFP into fibrils (Fig. 3 A). Second, at variance with 
the first setup, the ECM-producing HEK293 cells were removed 
using DOC, leaving behind LTBP-1–EGFP patches on the sub-
strate surface (Fig. 3 B). Third, LTBP-1–EGFP was purified 
from HEK293 cell supernatants and used to coat culture sub-
strates (Fig. 3 C and Fig. S2). Scanning electron microscopy 
demonstrated the ultrastructurally different ECM (Fig. 3). hDMfs 
Figure 2. ECM maturation and preremodeling affects TGF-1 activation by myofibroblasts. (A) hDMfs were grown for 2, 3, and 6 d, and lysates were 
used for Western blotting with vimentin as a loading control. (B) hDf- or hDMf-derived ECMs were decellularized using DOC and heat activated before 
total amounts of TGF-1 were determined by luciferase reporter assay. (C) hDMfs were seeded onto different preproduced ECMs and stimulated to contract 
with thrombin, and active TGF-1 was measured as a percentage of total TGF-1. (D) hDMfs were transfected with LTBP-1–EGFP and stained for LTBP-1 
and EGFP after 12 d. (E) EGFP, ED-A FN, and nuclei (blue) were stained in hDMf cultures after 2, 3, and 6 d. Bottom rows show magnified ECM regions. 
(F) The mean density of LTBP-1–EGFP fibrils was quantified from stained images. Bars: (D) 150 µm; (E, top) 25 µm; (E, bottom) 5 µm. Graphs show mean 
values and SDs from at least three independent experiments (*, P ≤ 0.05; and ***, P ≤ 0.005 using ANOVA followed by a post-hoc Tukey’s multiple 
comparison test). a.u., arbitrary unit.
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To test whether fibrillin-1 is important in mechanical priming of 
the ECM for TGF-1 activation, we produced ECM using mouse 
dermal fibroblasts bearing a fibrillin-1 mutation in LTBP-1 bind-
ing. Fibrillin-1 mutant murine fibroblasts produced and organized 
LTBP-1 (Fig. S4 C); however, the amount of total TGF-1 in the 
ECM was approximately fourfold lower than in wild-type cul-
tures. Consequently, preorganization did not change the amount 
of TGF-1 activated by hDMfs from fibrillin-1 mutant ECM, 
whereas preorganization improved TGF-1 activation by 1.5-fold 
from wild-type mouse fibroblast ECM (Fig. S4 D).
We next investigated the incorporation of LTBP-1 into an 
established ECM network by adding purified, soluble LTBP-1– 
EGFP to hDMfs that were precultured for 7 d to produce their 
own ECM (Fig. 4 E). The supplemented LTBP-1–EGFP pref-
erentially colocalized with preexisting ED-A FN fibrils (Fig. 4 E, 
inset), and the incorporation process was abolished in the pres-
ence of 20 µM blebbistatin (Fig. 4 E). Collectively, these results 
show that (a) the higher efficacy of hDMfs to form LTBP-1–
containing fibrils is not caused by higher production of FN, (b) 
hDMfs incorporate exogenous LTBP-1 into the ECM during 
FN fibrillogenesis, and (c) this process is cell mediated and de-
pendent on actin–myosin activity.
(Fig. 4 C) and hDMfs (Fig. 4 D) to 4 h on LTBP-1–EGFP-
coated substrates in FN-free culture medium. Quantification of 
LTBP-1–EGFP immunostaining and video microscopy analysis 
(Video 3) demonstrated that hDMfs assembled LTBP-1–EGFP 
almost instantaneously into fibrils, which were always positive 
for cell-derived ED-A FN. In accordance with previous obser-
vations, the LTBP-1 fibril count was higher for hDMfs than for 
hDfs (Fig. 4, C and D; and Fig. S3 C). Importantly, hDMfs also 
incorporated approximately twofold more LTBP-1–EGFP into 
fibrils than hDfs when cultures were supplemented with an ex-
cess of plasma FN (100 µg/cm2), either added to the medium 
(not depicted) or adsorbed onto the culture surface together 
with LTBP-1–EGFP (Fig. 4, C and D; and Fig. S3 C).
A previous study has demonstrated that LTBP-1 is increas-
ingly transferred from FN to fibrillin-1 during fibroblast culture 
ECM maturation (Zilberberg et al., 2012). In our fibroblast cul-
tures, FN and fibrillin-1 strongly colocalized ≤6 d of cell culture 
(Fig. S4 A). Moreover, mouse dermal myofibroblasts, being de-
fective for fibrillin-1 incorporation into the ECM and deficient in 
LTBP-1 binding to fibrillin-1 (Judge et al., 2004) formed LTBP-1/FN 
fibrillar structures, indicating that FN was sufficient for initial 
LTBP-1 incorporation into ECM fibrils (Fig. S4, B and C). 
Figure 3. Myofibroblasts are more efficient in LTBP-1 ECM organization than fibroblasts. (A–C) LTBP-1 substrates were produced by using LTBP-1–EGFP-
transfected HEK293 cells that were grown for 7 d (A), ECM was obtained after DOC treatment of LTBP-1–EGFP-transfected HEK293 cells that were grown 
for 7 d (B), and substrates coated with LTBP-1–EGFP were purified from supernatants of LTBP-1–EGFP-transfected HEK293 cells (C). The resulting ECM was 
used for scanning electron microscopy (SEM) and as substrates for hDfs and hDMfs. Fibroblastic cells were stained after 2-d growth for EGFP (green) and 
ED-A FN (red). Bars: (scanning electron microscopy images) 5 µm; (insets) 500 nm; (immunofluorescence images) 20 µm. LTBP-1–EGFP fibrils were quanti-
fied by image analysis from at least five images per three independent experiments to calculate mean values and SDs (***, P ≤ 0.005 using ANOVA 
followed by a post-hoc Tukey’s multiple comparison test). Insets show higher magnification views of cell-free ECM areas. a.u., arbitrary unit.
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to LTBP-1, we generated microcontact printed islet arrays of 
purified LTBP-1–EGFP with typical focal adhesion features 
(10 × 4 × 1.5 µm). hDMfs adhered specifically to the printed 
LTBP-1 at sites of vinculin-positive focal adhesions when seeded 
for 4 h in serum-free medium (Fig. 5 A). Focal adhesions forming 
on LTBP-1 islets contained 1 integrin, to a lesser extent 3 inte-
grin, and no integrin 5. Control prints using FN as a ligand dem-
onstrated that all tested integrins were expressed in hDMfs and 
localized to focal adhesions (Fig. 5 B). Next, we seeded hDMfs 
onto fully LTBP-1–coated substrates for 4 h in the presence of 
specific integrin-blocking antibodies and different RGD peptides 
(Fig. 5 C). Focal adhesion formation and cell spreading were re-
duced by all integrin blocking antibodies in order from strongest 
to weakest: 1, 3, and 5 integrin. All competitive integrin-
blocking peptides, but not controls, inhibited focal adhesion 
formation and cell spreading on LTBP-1 (Fig. 5 C). Strongest 
blocking was achieved with RGD as confirmed by quantifying 
the number of adherent hDMfs on LTBP-1–coated substrates 
(Fig. 5 D). These results indicate that hDMfs bind directly to the 
RGD sequence in LTBP-1 via integrins that possibly aid the ac-
tive organization of LTBP-1 into ECM fibrils in a cell tension–
dependent manner. Of the RGD-recognizing integrins expressed 
in hDMfs, 5 integrin seem to bind weakest by far.
Incorporation of LTBP-1 into  
disorganized ECM impairs mechanical 
activation of TGF-1
To further investigate how the higher preorganization of the 
hDMf ECM affects the efficacy of TGF-1 activation, we gener-
ated ECM with MEFs exhibiting cell–ECM protein interaction 
defects. MEFs derived from mice deficient for FAK (FAK/; 
Rajshankar et al., 2012) and 1 integrin (1/; Fässler and 
Meyer, 1995) and MEFs stably knocked down for filamin A 
(Kim et al., 2008) all produced disorganized ECM compared 
with wild-type MEF after 6 d of culture (Fig. S5 and Fig. 6 A). 
We continued with FAK/ MEFs that produced a disorganized 
ECM with low FN fibril density (Fig. 6 A) but expressed LTBP-1 
and FN at levels similar to those of wild-type MEFs (Fig. 6 B). 
This phenotype confirmed a previous study relating poor FN 
fibrillogenesis to the central role of FAK in fibrillar adhesion 
formation (Ilić et al., 2004). In addition to these studies, we 
herein show that FAK/ MEFs exhibit significantly lower ex-
pression levels of -SMA (Fig. 6 B) and exert lower contraction 
forces to deformable culture substrates (Fig. 6 C) as compared 
with wild-type MEFs. Despite the organizational differences, 
the amounts of total TGF-1 in the ECM of DOC-treated 
FAK/ and wild-type MEFs were similar (Fig. 6 D). In con-
trast, active TGF-1 levels differed significantly when hDMfs 
were seeded onto the decellularized murine ECM and induced 
to contract. hDMf contraction activated 50% of the total TGF-1 
stored in the ECM from wild-type MEFs but only 20% from 
the FAK/ ECM (Fig. 6 E). Baseline TGF-1 activation in the 
absence of contraction was low (15%) and comparable on 
both ECM types (Fig. 6 E). Addition of the contraction agonist 
thrombin to decellularized MEF ECM in the absence of hDMfs 
did not release any TGF-1, confirming the complete removal of 
MEFs and the specific action of thrombin on hDMf contraction 
Because human LTBP-1 contains an RGD consensus site, 
it is conceivable that v integrins participate in LTBP-1 incor-
poration into ECM fibrils and cell attachment to LTBP-1–coated 
substrates. To identify the integrin putatively mediating adhesion 
Figure 4. FN mediates LTBP-1 fibril formation and incorporation. (A and B) 
Substrates were coated with purified LTBP-1–EGFP and used to culture 
hDMfs transfected with siRNA against FN (siFN) or nonrelated control 
RNA (siNT; A) and FN/ MEFs or wild-type (WT) MEFs (B). (C) hDfs and 
hDMfs were seeded onto substrates coated with LTBP-1–EGFP alone or 
LTBP-1–EGFP mixed with an excess of FN (100 µg/cm2) and grown for 
4 h. (D) hDMfs were pregrown for 7 d before purified LTBP-1–EGFP was 
added to the culture medium for an additional 24 h in the presence or 
absence of 20 µM blebbistatin (blebbi). Experiments were performed in 
FN-depleted culture medium. All samples were stained for EGFP (green), 
FN (red), and nuclei (blue). (A–E) LTBP-1–EGFP fibrils (A–D) and stain-
ing intensity (E) were quantified by image analysis from at least five im-
ages per three independent experiments to calculate mean values and SDs 
(*, P ≤ 0.05; and ***, P ≤ 0.005 using ANOVA followed by a post-hoc 
Tukey’s multiple comparison test). Inset in E shows FN organization after 7 d of 
hDMfs without addition of LTBP-1–EGFP. Bars, 25 µm. a.u., arbitrary unit.
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Figure 5. Integrins mediate binding of myofibroblasts to LTBP-1. (A and B) Arrays of an islet with typical focal adhesion features (10 × 4 × 1.5 µm) 
were microcontact printed using purified LTBP-1–EGFP (A) or plasma FN as a control (B). After attachment for 4 h to microcontact printed arrays in 
the absence of serum, hDMfs were immunostained for the printed protein (red, false colored for LTBP-1–EGFP), vinculin, and integrin subunits 1, 3, 
and 5 (green). Insets show higher magnification views of select focal adhesion. (C) hDMfs were seeded onto LTBP-1–EGFP-coated substrates in the 
presence of blocking antibodies or cyclic peptides against integrin subunits 1, 3, and 5 or the RGD site. Focal adhesion formation was visualized 
with vinculin (green), and nuclei were stained with DAPI (blue). (D) The number of adherent hDMfs on LTBP-1–EGFP-coated substrates was quantified by 
image analysis. Graph shows mean values and SDs from at least three independent experiments (***, P ≤ 0.005; two-tailed paired t test). con, control. 
Bars: (main images) 20 µm; (insets) 5 µm.
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(unpublished data). Control experiments performed with active 
TGF-1–stimulated TMLCs verified that the reporter cell ac-
tivity did not depend on the organization level of their ECM 
substrate (Fig. 6 F).
Although attachment and spreading of hDMfs was similar 
on the different MEF-derived ECMs, ECM-induced phenotypic 
changes in hDMfs may have affected TGF-1 activation. To ex-
clude this possibility, we mechanically released active TGF-1 
using a cell-free assay (Fig. 6 F; Buscemi et al., 2011). Decellu-
larized MEF-derived ECM was incubated with anti-LAP–coated 
ferromagnetic beads for 1 h before force was applied through a 
magnetic field and active TGF-1 was measured (Fig. 6 G). 
Force-induced release of active TGF-1 from FAK/ MEF ECM 
was low (10% of total TGF-1) and not different from no-force 
and BSA-coated bead controls (Fig. 6 G). Conversely, pulling 
magnetic beads coated with the anti-LAP antibody resulted in 
an approximately threefold higher release of active TGF-1 
from wild-type MEF ECM as compared with FAK/ MEF ECM 
(Fig. 6 G). Collectively, these data demonstrated that mechani-
cal activation of TGF-1 from preorganized and mature ECM is 
more efficient than from disordered ECM.
Mechanical loading of LTBP-1 fibrils 
enhances TGF-1 release
Fibroblast-mediated ECM maturation involves straining of 
secreted fibrils, bundling, and proteolytic remodeling. To test 
whether prestraining the ECM alone would facilitate TGF-1 
activation, we used a mechanical strain device and highly ex-
pandable silicone culture membranes allowing an up to eight-
fold strain (Majd et al., 2011; Rosenzweig et al., 2012). The 
device was used to simulate and accelerate strain in the ECM 
that is induced by cells after several days or weeks in contrast to 
conventional strain devices and membranes that allow a maxi-
mum linear expansion of ≤1.3-fold, corresponding to length 
change associated with single cell contractions (Wipff et al., 
2009). hDfs were grown on nonstrained membranes (onefold) 
to produce ECM and removed after 6 d using DOC. The re-
maining LTBP-1/TGF-1–rich ECM was then strained in the 
absence of any cells. Immunofluorescence video microscopy of 
live-strained LTBP-1 revealed that, starting after a prestrain of 
1.4-fold, LTBP-1–containing fibrils straightened linearly with 
membrane strain to approximately twofold of their initial length 
at a membrane strain of 2.8-fold (Fig. 7, A and B; and Video 3). 
Figure 6. ECM disorganization suppressed TGF-
1 activation FAK/ MEFs, and wild-type MEFs 
were cultured for 6 d. (A) ECM production was 
assessed by immunofluorescence staining for FN 
(green) and nuclei (blue), and the mean density 
of FN fibrils was calculated from six images per 
three independent experiments. Bar, 100 µm. 
(B) Culture lysates were immunoblotted using vimen-
tin and GAPDH as loading controls. (C) Cells were 
seeded for 1 d onto silicone substrates, and wrinkle 
formation as a result of substrate deformation was 
quantified from phase-contrast images. Bar, 25 µm. 
(D) After 6-d culture, MEFs were removed using 
DOC, and total TGF-1 was measured after heating 
the remaining ECM. (E) hDMfs were seeded onto 
the decellularized MEF ECMs; active TGF-1 levels 
were measured as a percentage of total TGF-1 
without (baseline) and with thrombin-induced con-
traction. (F) TMLCs alone were seeded onto decellu-
larized ECM produced by MEF wild type (WT) and 
FAK/ and stimulated for 1 h with 0, 0.03, 0.06, 
0.12, 0.25, 0.50, and 1.0 ng/ml active TGF-1. 
Cells were further processed and assessed for lucif-
erase production (luminescence). The data shown 
are from a single representative experiment, and 
the experiment was completed once with three in-
dependent measurements. (G) Decellularized MEF 
ECM was incubated for 1 h with magnetic beads 
coated with BSA or anti-LAP (aLAP) antibody before 
magnetic force was applied, and active TGF-1 
was measured in the supernatant. Graphs show 
mean values and SDs from at least three indepen-
dent experiments (***, P ≤ 0.005 using ANOVA 
followed by a post-hoc Tukey’s multiple comparison 
test). a.u., arbitrary unit.
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even in the absence of cells, and (c) hDMf ECM reaches the 
TGF-1 activation threshold at lower strains than hDf ECM.
Alternatively, it is possible that strained ECM fibrils reveal 
a higher number of latent TGF-1 complexes that are available 
for integrin binding. To test this possibility, we produced one-
fold (no strain) and 1.9-fold prestrained hDf ECM as described 
in this paper that was incubated with anti-LAP antibody–coated 
fluorescent microspheres for 5 min. After rigorous washing, the 
number of beads remaining adherent per LTBP-1 fibril area in 
the image field was similar in both conditions, demonstrating 
that strain did not reveal “cryptic” LAP (Fig. 7 E). We further 
excluded that active TGF-1 absorbs differently to ECM under 
different strain conditions (Fig. 7 F). Therefore, we conclude 
that the strain introduced into LTBP-1 fibrils primes the latent 
complex for TGF-1 by myofibroblasts contraction.
Discussion
In a previous publication, we showed that fibroblasts directly ac-
tivate TGF-1 by exerting forces to the latent complex and that 
cultured rat lung myofibroblasts release more active TGF-1 
from their ECM than from fibroblasts (Wipff et al., 2007). These 
findings were explained with the higher contractile activity of 
myofibroblasts over fibroblasts (Hinz et al., 2001a). However, re-
cent structural and single molecule force spectroscopy studies 
have indicated that forces as low as 40 pN, corresponding to the 
action of few myosin II motors, are sufficient to induce confor-
mational changes in LAP that will lead to the release of TGF-1 
At strains larger than threefold, the ECM was detaching from 
the membrane and thus not investigated (unpublished data). 
hDMfs were then seeded on the differently strained ECM and 
induced to contract with thrombin and TRAP-6 in select condi-
tions (Fig. 7 C). hDMf contraction activated 7% of total TGF-1 
at a prestrain of 1.7-fold, 13% from 1.8-fold prestrained 
ECM, and 61% from 1.9-fold prestrained ECM (Fig. 7 C). 
Western blotting for phospho-Smad2 in subsequently lysed 
hDMfs confirmed that increasing prestrain in the ECM resulted 
in increasing levels of active TGF-1 and downstream signal-
ing (Fig. 7 C).
Because no TGF-1 was activated by contraction of 
reseeded hDMf from hDf ECM that has been prestrained by 
more than twofold, we hypothesized that larger strains can 
lead to release of TGF-1 from the latent complex even in the 
absence of counteracting cell integrins. We tested this possi-
bility by producing LTBP-1 ECM using hDfs and hDMfs and 
removing the cells after 6 d with DOC. The cell-free ECM 
was then strained from 1.0–2.8-fold. Active TGF-1 levels in 
the supernatant were measured after each incremental strain 
of 0.1-fold (Fig. 7 D). After strains of 2.0, 2.1, and 2.2, re-
spectively, 11, 23, and 28% of the total TGF-1 was activated 
and released from hDMf ECM. In contrast, release of active 
TGF-1 from hDf ECM did not occur at strains <2.4-fold. 
Collectively, these results indicate that (a) prestraining ECM 
alone is sufficient to increase the release of active TGF-1 by 
subsequent hDMf contraction, (b) high strain is able to me-
chanically open the latent complex for active TGF-1 release 
Figure 7. Prestraining LTBP-1–containing ECM enhances sub-
sequent TGF-1 release. hDMfs grown on relaxed highly ex-
pandable silicone membranes were removed after 6 d using 
DOC. (A) The cell-free DOC-insoluble ECM was stained without 
fixation for LTBP-1 and visualized during membrane expansion 
from relaxed (onefold) to 2.8-fold strains. Selected fibrils (boxes) 
were magnified and followed in incremental steps of a 0.2-fold 
membrane strain. (B) Illustration of the strain device opening and 
membrane expansion. Strain of LTBP-1–containing fibrils was 
measured as fold length change compared with initial length 
and plotted against membrane surface expansion. The data 
shown are from a single representative experiment out of three 
repeats. (C) hDMfs were seeded onto nonstrained (onefold) and 
prestrained decellularized ECM (≤2.2-fold). Cell contraction was 
induced in every condition using thrombin and TRAP-6 in select 
conditions, and release of active TGF-1 was quantified as the 
percentage of total TGF-1. Western blotting was performed for 
phospho- and total Smad2 in subsequently lysed myofibroblasts. 
(D) The decellularized ECM produced by either hDMfs or hDfs 
was strained in the absence of cells by expanding the membrane 
≤2.8-fold, and active TGF-1 released into the supernatant was 
measured at every 0.1-fold increment. (E) Decellularized ECM 
labeled for LTBP-1 (red) and green fluorescent microspheres at 
strains of 1.0- and 2.8-fold. Arrows indicate microspheres bound 
to LTBP-1 fibrils. The number of microspheres in the image field 
was quantified and normalized to the area covered by LTBP-1 
fibrils. (F) 1 ng/ml active TGF-1 was added for 1 h to cell-
free hDMf-derived ECM that was either nonstrained (onefold) or 
strained 1.9-fold. Samples were rigorously washed three times, 
ECM was subsequently lysed, and levels of ECM-contained TGF-1 
were measured using TMLCs. The graph shows mean values and 
SDs from at least three independent experiments. Bars: (main 
images) 20 µm; (magnified images) 4 µm.
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be sufficiently stiff to resist the cell forces needed to release 
TGF-1 from its LAP straitjacket. Consistently, activation of 
TGF-1 from the ECM depends on binding of LAP to LTBP-1, 
which in turn has to be linked to the ECM (Taipale et al., 1994; 
Annes et al., 2004; Fontana et al., 2005). However, the view of 
stiffness-controlled TGF-1 activation may be oversimplified 
in light of our results showing that prestraining latent TGF-1–
containing ECM on silicone membranes with unchanged elastic 
modulus was sufficient to enhance TGF-1 activation by sub-
sequent cell contraction. Nevertheless, the bulk stiffness of the 
material may have a secondary effect by determining the orga-
nization state of the cell-derived ECM by regulating the remod-
eling activity of the adhering cells before TGF-1 activation 
(Godbout et al., 2013).
In contrast to elastic cell culture polymers, the ECM of 
normal and fibrotic connective tissues is subject to strain stiff-
ening (Storm et al., 2005; Discher et al., 2009). Our results sug-
gest that a cell remodeling strain stiffens LTBP-1–containing 
ECM and thereby primes latent TGF-1 for subsequent activa-
tion. The pathological remodeling and stiffening of scar tissue 
can be understood as the overall outcome of subcellular con-
tractions with small length changes (400 nm) but repetitive 
occurrence (40 contractions/h) as measured in cultured fibro-
blasts (Follonier Castella et al., 2010a). Because such subcellu-
lar contractions theoretically accumulate to 2.5 mm per week 
in vitro, it may take weeks, months, or years for fibrotic scars to 
mature (Tomasek et al., 2002; Follonier Castella et al., 2010b). 
ECM fibril straightening is greatly accelerated in cultures of 
myofibroblasts that are contracting with higher frequency and 
amplitude than fibroblasts (Follonier Castella et al., 2010a). In 
our experiments, mechanical release of TGF-1 was dependent 
on the extent of ECM preremodeling and thus more efficient 
from a myofibroblast-produced ECM than from fibroblast- 
produced ECM. The fact that induced acute myofibroblast con-
traction results in larger absolute length changes than fibroblast 
contraction is likely responsible for their higher capacity to ac-
tivate TGF-1 from the same preformed ECM.
Prestraining ECM on highly expandable culture mem-
branes demonstrated that even the quasi–two-dimensional ECM 
of cultured fibroblasts provides sufficient buffer (slack) to allow 
1.4-fold length changes before fibrils are visibly engaged, and 
it requires an 2.8-fold strain to liberate TGF-1 in the absence 
of cells. In contrast, myofibroblast ECM is 25% more pre-
strained than the ECM of fibroblasts in our culture conditions as 
extrapolated from the release of TGF-1 at a lower strain (two-
fold). It remains elusive whether TGF-1 release in the absence 
of any cells was caused by ECM damage by “overstrain” or 
whether a physiological mechanism is conceivable that allows 
stress liberation of TGF-1 without integrin pulling on the 
RGD site of LAP. A similar, cell cytoskeleton-independent ef-
fect was reported for the strained tendon, which is characterized 
by highly organized and strained collagen fibrils (Maeda et al., 
2011). It has been proposed that a normal ECM strain in the 
tendon releases physiological levels of TGF-1 that regulate 
tenocyte function. Tendon injury and loss of the mechanopro-
tective collagen structure were shown to result in dramatically 
increased active TGF-1 levels (Maeda et al., 2011).
(Buscemi et al., 2011; Shi et al., 2011). Consistently, low contrac-
tile epithelial cells are also able to activate TGF-1 through 
integrin-mediated force transduction (Giacomini et al., 2012). 
One possible explanation for this apparent contradiction is that the 
efficacy of force-mediated TGF-1 activation depends on the me-
chanical properties of the myofibroblast ECM that are established 
before the actual activation step occurs. Here, we demonstrate 
in vitro and in vivo that myofibroblasts deposit similar levels of la-
tent TGF-1 into the ECM but organize the LTBP-1 into straighter 
and denser fibrils as compared with fibroblasts. By offering myo-
fibroblasts latent TGF-1–containing ECM of identical composi-
tion but different prestrain, we revealed a clear dependence of 
TGF-1 activation on the level of ECM organization at the time 
of force exertion to the latent complex. We propose a model in 
which cell-mediated remodeling leads to gradual straining of 
LTBP-1/TGF-1–containing ECM fibrils, analogous to loading a 
mechanical spring (Fig. 8).
Mechanical preloading of the ECM will have important 
implications for the availability of profibrotic TGF-1 during 
normal tissue repair and development of fibrosis. Organ fibrosis 
comprises the excessive secretion and contraction of ECM by 
fibroblastic cells and augments tissue stiffness (Wynn, 2008; 
Hinz, 2012; Henderson and Sheppard, 2013; Klingberg et al., 
2013). We and others have previously shown that growth on 
culture substrates with low elastic modulus reduces TGF-1 ac-
tivation by cell contraction (Wipff et al., 2007; Giacomini et al., 
2012). These findings led to the conclusion that the ECM has to 
Figure 8. ECM prestrain generated by myofibroblast contraction affects 
TGF-1 activation. Fibroblasts secrete ECM that is rich in FN (green) and 
the large latent complex of TGF-1 (LTBP-1, LAP, and TGF-1). Fibroblast-
to-myofibroblast differentiation occurs during physiological (normal wound 
healing) and pathological (fibrosis) tissue remodeling. Myofibroblasts are 
characterized by -SMA–positive stress fibers (red) enabling these cells to 
exert high contractile activity and forces transmitted to the ECM at sites of 
integrins. The gradual straitening and straining of ECM fibrils, containing 
FN and LTBP-1, prime the latent TGF-1 complex for subsequent activation. 
At sufficient prestrain, minimal additional length changes in the ECM (i.e., 
small contractions) will be sufficient to release active TGF-1 by inducing 
a conformational change in LAP. Hence, the mechanical preloading of the 
ECM determines the trigger point for TGF-1 activation driving the vicious 
loop of myofibroblast self-activation.
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ECM shows that LTBP-1 fibril assembly can occur after secre-
tion. Importantly, we show that blocking fibroblastic cell con-
traction inhibited the incorporation of endogenous purified 
LTBP-1 into a preexisting FN network, indicating a cell-driven 
and active process. It remains to be shown whether fibroblasts 
use integrins to promote LTBP-1 fibril assembly or whether a 
cell-derived strain generates assembly sites in FN for LTBP-1 
binding, similar for what has been described for FN autofibril-
logenesis (Zhong et al., 1998; Smith et al., 2007; Singh et al., 
2010). Experiments performed with prestrained cell-free ECM 
render it unlikely that strain-induced FN autofibrillogenesis al-
lows increased LTBP-1 binding and thereby contributes to in-
creased TGF-1 activation, at least in our culture experiments. 
In vivo, however, this possibility has yet to be tested. The fact 
that myofibroblasts formed focal adhesions with microcontact-
printed LTBP-1 and that blocking of RGD binding integrins re-
duced adhesion of myofibroblasts to LTBP-1–coated substrates 
suggests that fibroblastic cells directly bind LTBP-1. The RGD 
sequence described in human LTBP-1 serves as a possible rec-
ognition site (Hyytiäinen et al., 2004). However, rodent LTBP-1 
and widely expressed LTBP-3 (Saharinen et al., 1999) do not 
contain RGD, which may thus not be the only cell binding site 
in LTBPs. Although direct integrin binding may contribute to 
LTBP-1 recruitment to existing FN fibrils, it seems insufficient 
for LTBP-1 fibrillogenesis in the absence of FN.
It will be a future challenge to develop specific strategies 
interfering with the mechanical loading of the fibroblast/myofi-
broblast ECM with respect to TGF-1 activation. It is amply 
clear that defects in essential components of the FN and micro-
fibril ECM lead to a variety of TGF-1–related diseases (Ramirez 
and Rifkin, 2009; Doyle et al., 2012; Baldwin et al., 2013). The 
sole inhibition of LTBPs binding to the ECM is unlikely to be 
efficient as an antifibrosis therapy because fibrillin-1 mutants 
defective for LTBP-1 binding exhibit TGF-1 hyperactive phe-
notypes. Alternatively, integrins represent possible antifibrotic 
targets that provide relative cell and tissue specificity in the con-
text of latent TGF-1 activation (Gerber et al., 2013; Henderson 
et al., 2013; Hinz, 2013).
Materials and methods
Ethics statement
Human material was provided by B.A. Alman, and the use was approved 
by the Institutional Review Board of the Hospital for Sick Children. Written 
informed consent was obtained from patients for the use of the material.
Animal experiments
On a total of 20 female Wistar rats (200–220 g), full-thickness 20 × 20–mm 
wounds were produced in the middle of the dorsum. Wounds were al-
lowed to heal either spontaneously (control) or were subject to mechani-
cal stress by fixing the edges of the wound tissue on a plastic frame that 
prevents wound closure and retains the size of the open wound over time 
(stressed). Authorization of the local animal ethic committees was obtained 
as previously described (Hinz et al., 2001b). Rats were sacrificed by CO2 
anesthesia, and wound granulation tissue was harvested after 3, 6, and 
9 d after wounding. For immunofluorescence staining of rat tissues, 5-µm 
sections were fixed with 100% acetone for 15 min at 20°C and then 
dried for 30 min at RT. After adjusting to RT, sections were rinsed in PBS, 
blocked with 1% BSA for 30 min, and stained with primary antibodies 
ED-A FN (1:200; sc-59826; Santa Cruz Biotechnology, Inc.) and LTBP-1 
(1:100 [MAB388; R&D Systems] or 1:250 [Ab39; a gift from C.-H. Heldin, 
Uppsala University, Uppsala, Sweden]) followed by 30-min secondary 
fluorescently labeled antibodies.
Linking the activation of latent TGF-1 to the organi-
zation state of the ECM will provide a mechanical threshold 
to generate and/or sustain myofibroblasts, which develop 
their contractile activity by expressing -SMA in response to 
TGF-1 (Hinz et al., 2001a). In the poorly organized but latent 
TGF-1–rich provisional ECM established after acute injury 
(Brunner and Blakytny, 2004), TGF-1 activation by cell trac-
tion will be inefficient, and myofibroblasts will not develop. 
In a sufficiently prestrained ECM, even the low contractile 
forces exerted by migrating fibroblastic cells will promote 
latent TGF-1 activation. This model can answer the clas-
sical hen-and-egg question of whether ECM stiffening must 
occur first to induce myofibroblast differentiation or whether 
myofibroblast contraction must occur first to stiffen the ECM. 
Importantly, secretion of latent TGF-1 by myofibroblasts 
into an already straightened fibrotic ECM will provide a much 
faster trigger for TGF-1 activation than required during fi-
brosis development. This property may at least partly explain 
the fact that decellularized ECM derived from fibrotic but not 
normal lung tissue instructs de novo seeded cells to become 
fibrotic even in the absence of exogenous TGF-1 (Booth 
et al., 2012). It becomes indeed increasingly accepted that the 
biochemical and biophysical properties of fibrotic ECM pro-
vide sufficient cues to drive resident and recruited cells into a 
disease state (Berry et al., 2006; Shimbori et al., 2013).
The question remains open whether enhanced activa-
tion of TGF-1 requires specific prestrain in LTBP-1 itself 
or whether LTBP-1 passively piggybacks on overall ECM 
remodeling. To date, there is no evidence for formation of 
LTBP-1–exclusive fibrils. Our results show that LTBP-1 is se-
creted independently of FN, but its fibrillar organization appears 
to depend on the presence of FN in the ECM. This interdepen-
dence was particularly evident in fibroblasts that overexpress 
LTBP-1 under a constitutively active promoter; in these cells, 
the physiological sequence of FN preceding LTBP-1 secretion 
(Dallas et al., 2005; Koli et al., 2005) is uncoupled. Our obser-
vations are consistent with the idea of FN acting as a master 
template in immature ECM for the subsequent recruitment and 
organization of other ECM proteins, including latent TGF-1 
binding proteins (LTBPs; Dallas et al., 2005; Koli et al., 2005), 
fibrillin-1 (Isogai et al., 2003; Chaudhry et al., 2007; Ono et al., 
2009; Sabatier et al., 2009, 2013), fibulin-1 (Godyna et al., 1995), 
and collagen (Velling et al., 2002; Isogai et al., 2003) as well as 
the indirect role of heparan sulfate proteoglycans in LTBP-1 
to FN binding (Chen et al., 2007). It is still unclear whether 
fibrillin-1 is another essential component to mechanically prime 
the ECM for subsequent TGF-1 activation. The ECM produced 
by fibrillin-1 mutant murine fibroblasts in our experiments was 
too low in total TGF-1 to exhibit clear differences in TGF-1 
activation before and after prestrain. Furthermore, because fi-
brillin-1 and FN largely colocalize in 6-d fibroblast cultures, 
it is reasonable to assume that the mechanism of ECM strain 
controlling TGF-1 activation is principally independent from 
the molecular nature of the LTBP-1 binding protein provided 
that cell force can be transmitted.
Our new finding that fibroblastic cells incorporate non-
endogenous purified LTBP-1 into preexisting or developing FN 
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phalloidin Alexa Fluor 488 and 568 (1:100; Life Technologies) and DAPI 
(1:50; Sigma-Aldrich) were used, respectively.
Image acquisition, processing, and quantitative analysis
Fluorescence microscopy images were acquired with an upright microscope 
(Axio Imager; Carl Zeiss) equipped with a camera (AxioCam HRm; Carl 
Zeiss), ApoTome.2 structured illumination, and ZEN software (Zeiss-1; Carl 
Zeiss). Fig. 1 A images were taken with Plan Apochromat objectives (40×, 
NA 1.2 [Fig. 1 A, top two rows] and 63×, NA 1.4, oil differential interfer-
ence contrast at RT; Carl Zeiss) on Zeiss-1 using ApoTome.2 structured illu-
mination to calculate confocal optical sections. Fig. 1 B (top) images were 
taken with a Plan Fluar objective (20×, NA 0.75 at RT, air; Carl Zeiss) on 
Zeiss-1. Fig. 1 B (bottom) images were taken with a Plan Fluar objective (40× 
oil immersion, NA 1.30 at RT; Nikon) at the Center for Microfluidics in 
Chemistry and Biology at the University of Toronto with a confocal micro-
scope (A1; Nikon) equipped with two camera systems, a Retiga 2000R Fast 
1394 camera (QImaging) and a confocal imaging system running NIS- 
Elements software (Confocal-1; Nikon). All Fig. 2 images were acquired on 
Confocal-1 with a Plan Fluar objective (40×, NA 1.30, oil immersion at RT; 
Nikon). Fig. 3 scanning electron microscope images were acquired on an 
environmental scanning electron microscope (XL-30; Phillips) at the Depart-
ment of Pathology and Laboratory Medicine (Mount Sinai Hospital). Samples 
were prepared according to imaging facility requirements. In brief, samples 
were fixed with glutaraldehyde and dehydrated stepwise to 100% ethanol. 
After critical point drying, samples were gold coated with a low-vacuum 
sputter. Fig. 3 (A and B) confocal images were taken on a confocal micro-
scope system (DMIRE2; Leica), from here on referred as Confocal-2, with an 
HCX Plan Apochromat CS (40×, NA 1.25, oil immersion at RT; Leica) objec-
tive and processed with LAS Software (Leica). Fig. 3 C and all confocal im-
ages from Fig. 4 were taken on Confocal-1 with a Plan Fluar objective (40×, 
NA 1.30, oil immersion at RT; Nikon). Fig. 5 images of microcontact print-
ing were taken on Zeiss-1 with a Plan Apochromat objective (63×, NA 1.4, 
oil differential interference contrast at RT; Carl Zeiss). Images in Fig. 6 A 
were taken on Zeiss-1 with a Plan Fluar objective (20×, NA 0.75 at RT; Carl 
Zeiss), and Fig. 6 C images were taken live with Zeiss-1 and a water immer-
sion Apochromat objective (40×, NA 1.0 at RT; Carl Zeiss). Fig. 7 images 
are obtained from Video 1 processed with MetaMorph software (Molecular 
Devices). Video 1 was taken on a microscope (Axiovert 135M; Carl Zeiss) 
with a camera (C10600 ORCA-R2; Hamamatsu Photonics) and a Plan Fluar 
objective (10×, NA 0.5 at RT; Carl Zeiss). Fig. S4 B images were taken on 
Confocal-1 with a Plan Fluar objective (40×, NA 1.30, oil immersion at RT; 
Nikon). Fig. S5 images were taken on Zeiss-1 with a Fluar objective (20×, 
NA 0.75 at RT; Carl Zeiss). All Carl Zeiss microscopes were operated with 
ZEN software.
Quantitative image analysis was performed using ImageJ (National 
Institutes of Health) and customized macros (supplemental material). Fig-
ures were assembled with Photoshop CS5 (Adobe). ED-A FN and LTBP-1 
fibril count and density were determined from images taken from tissue 
slices and cell cultures. In brief, single-channel images were converted to 
8-bit grayscale, and thresholding was applied to remove background de-
pending on experimental conditions. Particle events were counted, and 
density was analyzed for events with a size larger than 2 × 2 pixels and 
0–1 circularity.
Immunoprecipitation and Western blotting
For Western blots, vinculin, -SMA, and vimentin were separated on 10%, 
and FN, ED-A FN, FAK, GPF (reduced conditions), and LTBP-1 (nonre-
duced conditions) were separated on 8% SDS-PAGE gels. Gels were trans-
ferred to nitrocellulose membranes using semidry transfer technique at 
18 mAmps/gel and 20 V for 16 h or overnight. Protein membranes were 
blocked with 5% skim milk, and primary antibodies were detected with 
fluorescently labeled anti–mouse 680-nm and anti–rabbit 800-nm IRDye 
secondary antibodies (1:10,000; LIC-926-68020 and LIC-926-32211; 
LI-COR Biosciences). Signals were detected with an Fx imaging system 
(Odyssey; LI-COR Biosciences).
TGF-1 bioassay
Active TGF-1 was quantified using TMLCs, which produce luciferase under 
control of the PAI-1 promoter in response to TGF-1 (provided by D.B. Rifkin, 
New York University, New York, NY; Abe et al., 1994). Co-culture or decel-
lularized ECM experiments were performed by seeding TMLCs directly onto 
the first cell layer or DOC-insoluble ECM. Fibroblast and myofibroblast con-
traction was then induced by 0.5 U/ml thrombin for 1 h with subsequent 
media change for 16 h. TMLCs were lysed with cell culture lysis reagent 
(1:5; Promega) and assessed with a luciferase assay kit (Promega) using a 
Cell culture and reagents
Fibroblasts were explanted from human dermal tissue–derived human 
tissue sections. In brief, tissues were cut into 1-mm3 cubes, attached to tis-
sue culture plates, and immersed in standard DMEM (Life Technologies), 
supplemented with 10% fetal bovine serum (Sigma-Aldrich), and penicil-
lin/streptomycin (Life Technologies). Cells were allowed to migrate out of 
tissues for 10 d before the first passage. To promote hDf-to-hDMf differenti-
ation, 2 ng/ml TGF-1 (100-B-001; R&D Systems) was added for 6 d. The 
Flp-In 293 cell line (gift from P. Jurdic, Université de Lyon, Lyon, France) 
was maintained in standard medium supplemented with Zeocin (1:1,000; 
R250-05; Life Technologies). Flp-In 293 cells from a single-cell clone were 
transfected with pSecTag–LTBP-1–EGFP, and a stable HEK293–LTBP-1–
EGFP (HEK293–LTBP-1) cell line was derived by fluorescence-activated cell 
sorting and limited dilution. HEK293–LTBP-1 cells were maintained under 
hygromycin B (1:50; 10687-010; Life Technologies) selection. hDfs and 
myofibroblasts, wild-type MEFs (CRL-2645T; ATCC), FAK/ (CRL-2644; 
ATCC), filamin A knockdown, created by stable transfection of NIH3T3 
cells with shRNA against filamin A were a gift (Kiema et al., 2006; Shifrin 
et al., 2009), and integrin 1/ knockout cells (GD25; Fässler et al., 
1995) were gifts from C. McCulloch (University of Toronto, Toronto, On-
tario, Canada). For integrin 1/ knockout cells, the second exon of the 
1integrin gene in embryonic stem (ES) cells was disrupted with a gene 
trap vector with a -galactosidase–neomycin fusion DNA. ES cells were im-
mortalized with recombinant retroviruses that transduced the SV-40 large 
T. A single clone was established that was mutated in both alleles. The 
homozygous mutant clone did not produce integrin 1 mRNA or protein 
(Fässler et al., 1995). FN/ MEFs were developed together with R. Fässler 
(Max Planck Institute of Biochemistry, Munich, Germany). In brief, ES cells 
were isolated form embryonic day 14.5 FN floxed embryos, immortalized 
via retroviral transduction of SV-40 large T antigen, cloned, and treated 
with adenoviral Cre to delete the floxed FN alleles. The FN targeting vector 
spanned the region from the promoter to the second intron. For the floxed 
FN allele, loxP sites were confirmed within the 5-untranslated region and 
within the first intron. Cre-mediated recombination at these two loxP sites 
removed the start codon, signal sequence, and the exon/intron border 
of exon 1 to generate the null allele (Sakai et al., 2001). Wild-type and 
fibrillin-1 C1039G/+ mutant mouse dermal myofibroblasts (gift from 
H. Dietz, Johns Hopkins University School of Medicine, Baltimore, MD; 
Judge et al., 2004) were maintained in standard culture media.
Plasmids and purification of LTBP-1–EGFP
The pSecTag–LTBP-1–EGFP plasmid was created by subcloning the previ-
ously published LTBP-1–EGFP sequence in frame of pSecTag/FRT/V5-His-
TOPO vector (Life Technologies; Buscemi et al., 2011). Correct integration 
was confirmed by sequencing the insert both ways at 5-TCAG-3 (SickKids 
Hospital, Toronto, Canada). LTBP-1 was purified from serum-free conditioned 
media of HEK293–LTBP-1. In brief, conditioned medium was collected and 
dialyzed against Dulbecco’s PBS (Life Technologies) before it was run over 
an ion metal affinity chromatography column with HIS-Select Nickel Affinity 
Gel (Sigma-Aldrich). Columns were washed with wash buffer containing 
0, 10, or 15 mM imidazole. Fractions containing LTBP-1 were eluted with 
250 mM imidazole (Fig. S2).
Immunofluorescence
Before immunofluorescence staining of cultured cells, samples were simulta-
neously fixed, and permeabilized in 3% paraformaldehyde. In vitro samples 
were fixed with 3% paraformaldehyde for 10 min, washed with PBS, and 
then permeabilized with 0.2% Triton X-100 for 5 min. Primary antibodies used 
in this study were -SMA (mouse IgG2a; clone SM1; a gift of G. Gabbiani, 
University of Geneva, Geneva, Switzerland), vinculin (rabbit; 1:400; 
ab11194; Abcam), FN (rabbit; 1:400; F3648; Sigma-Aldrich), ED-A FN 
(mouse IgG1;1:200; sc-59826; Santa Cruz Biotechnology, Inc.), LTBP-1 
(mouse IgG1 [1:100; MAB388; R&D Systems] or rabbit [1:250; Ab39]), 
fibrillin-1 (rabbit; 1:500; raised against the recombinant, soluble N-terminal 
half of fibrillin-1 fragment; gift from D.P. Reinhardt, McGill University, Mon-
treal, Quebec, Canada; Sabatier et al., 2009), integrin 1 (mouse IgG1; 
1:50; ab30394; Abcam), integrin 3 (mouse IgG1; 1:50; MAB1974; EMD 
Millipore), and integrin 5 (rabbit; 1:50; ab15459; Abcam). Recombinant 
LTBP-1 was stained with anti-GFP antibodies (rabbit [1:200; ab290; Abcam] 
and mouse IgG1 [1:200; ab291; Abcam]) to achieve higher detection sen-
sitivity than anti–LTBP-1 antibodies. Secondary antibodies used were goat 
anti–mouse IgG Alexa Fluor 568 (1:100; A-11004; Life Technologies), goat 
anti–mouse IgG1 FITC (1:100; 1070-02; SouthernBiotech), goat anti–mouse 
IgG2a TRITC (1:100; 1080-03; SouthernBiotech), and goat anti–rabbit-TRITC 
and -FITC (1:100; F9887; Sigma-Aldrich). To stain F-actin and nuclear DNA, 
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a post-hoc Tukey’s multiple comparison test, and we set the significance 
level at P = 0.05. For experiments comparing fibroblasts versus myofibro-
blasts, we performed a two-tailed paired t test. When applicable, differ-
ences were considered to be statistically significant and indicated with *, 
P ≤ 0.05; **, P ≤ 0.01; and ***, P ≤ 0.005. Error bars represent SD.
Online supplemental material
Fig. S1 provides control experiments demonstrating that the TGF-1 used 
to produce hDMfs in early passages does not interfere with active TGF-1 
measurements in later passages. Fig. S2 characterizes purified LTBP-1. Fig. S3 
shows dynamic organization of HEK293 cell-derived LTBP-1 ECM by myo-
fibroblasts. Fig. S4 elucidates the role of fibrillin-1 in LTBP-1 organization 
using MEFs that produce a LTBP-1 binding-deficient mutant of fibrillin-1. 
Fig. S5 summarizes the different mouse fibroblast models that were evalu-
ated to produce an ECM with identical composition but defective organiza-
tion compared with wild-type cells. Video 1 corresponds to the image 
sequence shown in Fig. 7 and demonstrates dynamic strain of LTBP-1 ECM. 
Video 2 illustrates dynamic organization of LTBP-1 by hDMfs grown on top 
of LTBP-1–producing HEK293 cells. Video 3 shows LTBP-1 organization by 
myofibroblasts in co-culture with HEK293 cells. A ZIP file is also provided 
that contains a supplementary macro to quantify cell contractile activity 
from wrinkling substrates. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201402006/DC1.
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luminometer (Centro LB; Berthold Technologies). To asses TGF- levels from 
culture supernatants, TMLCs (60,000 cells/cm2) were allowed to adhere for 
4 h before being subjected to conditioned media, which was native (active 
TGF-) or heat activated (total TGF-) for 10 min at 80°C for 1 h. TMLCs 
were then grown in medium containing 1% FBS for 16 h. 5 ng/ml TGF-1–
specific blocking antibody (AF-101-NA; R&D Systems) was used to confirm 
that TGF-1 is the main TGF- isoform activated in our cultures. If not stated 
otherwise, all results were corrected for TMLC baseline luciferase production 
in the absence of TGF-1 and thrombin activation. In all conditions, active 
TGF-1 was normalized to total TGF-1.
ECM labeling with fluorescent microspheres
Red fluorescence microspheres with 1-µm diameter (Life Technologies) were 
coated with the anti–LAP-1 antibody. ECM on highly elastic silicone rubber 
membranes was decellularized and stained for LTBP-1 and anti–mouse IgG1-
FITC as described in this paper. ECM was decellularized with DOC buffer 
(150 mM NaCl, 50 mM Tris-HCl, 1% NP-40, and 0.5% sodium DOC) treat-
ment. In brief, cells were washed three times with PBS, ice-cold DOC buffer 
was added for 5–10 min at 4°C, and cell debris was aspirated. Subsequent 
washes with PBS cleaned ECM of remaining debris. Nonstrained and 
1.9-fold strained ECMs were incubated with an excess of microspheres for 
5 min followed by extensive washing to remove unbound spheres. Five ran-
dom images of LTBP-1 fibril area and spheres were taken in three independent 
experiments and analyzed for the amount of LTBP-1 area and bound spheres.
Microcontact printing and cell adhesion assay
To visualize direct binding of cells to purified LTBP-1, we used microcontact 
printing (Goffin et al., 2006). In brief, polydimethylsiloxane stamps exhibit-
ing islet topographies with dimensions of 10-µm length, 1.5-µm width, and 
4-µm spacing were coated with 0.2 µg/ml LTBP-1 or FN (FC010; EMD Milli-
pore) for 1 h. Protein prints were created on plastic coverslips, and protein-
free areas were passivated with poly-l-lysine–polyethylene glycol for 10 min. 
Myofibroblasts were seeded on prints in serum-free media for 4 h before 
being processed for immunostaining. For cell adhesion quantification, 
tissue culture plastic wells were coated with 20 µg/ml LTBP-1, and hDMfs 
were seeded for 4 h in the presence of cyclic peptides antagonizing 10 µM 
RGD (12135-010; Gibco), 10 µM control RGE (12139-010; Gibco), integ-
rins v3/v5 (EMD121974; Cilengitide), v3 integrin (EMD66203), 
and scrambled control (EMD135981; Merck). Blocking antibodies were 
used directed against 10 µg/ml integrins 1 (MAB1965; EMD Millipore), 
3 (MAB1976; EMD Millipore), and 5 (MAB1961; EMD Millipore). Addi-
tional controls were 10 µM RGE and human IgG (I9135; Sigma-Aldrich). 
Samples were rigorously washed three times before cells were fixed for quan-
tification and staining.
ECM prestrain assay
To strain decellularized ECM, we continuously expanded silicone culture 
substrates with a mechanical strain device (Cellerator; Cytomec GmbH) 
and highly expandable silicone rubber culture membranes, chemically 
functionalized for cell adhesion and coated with covalently bound rat tail 
collagen type I at 10 µg/ml (354236; BD) as previously described (Wipff 
et al., 2009). Fibroblastic cells were grown for 7 d and removed with DOC 
to preserve ECM only (Wipff et al., 2007). Membranes and attached ECM 
were then uniaxially strained from 1.0 (nonstrained)- to 2.8-fold in 0.1% 
increments before hDMfs were seeded and grown for 4 h on the DOC- 
insoluble ECM. Finally, cell contraction was induced, and TGF-1 activa-
tion was measured. In one series of experiments, TGF-1 activation was 
measured during ECM prestrain in the absence of any cells.
Cell contraction assay
Cell contractility was assessed using deformable silicone substrates as pre-
viously described (Godbout et al., 2013). In brief, polydimethylsiloxane 
substrates with a Young’s modulus of 2 kPa were coated with 10 ng/ml 
FN. Cells were seeded at a concentration of 2,500 cells/cm2, and wrinkle 
formation on substrates was observed after 24 h in culture. Live-phase con-
trast images were acquired with an inverted microscope (Axiovert 135M; 
40× objective) and analyzed using ImageJ software (National Institutes of 
Health) by thresholding for phase-bright wrinkles and analyzing the sur-
face area covered by identified particles in the resulting binary images. 
Relative contraction was expressed as the image area covered by wrinkles 
as previously described (Balestrini et al., 2012).
Statistical analysis
When applicable, data are presented as means ± SD. We assessed differ-
ences between groups with an analysis of variance (ANOVA) followed by 
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